• 1. Dissociative electron attachment to HGaF4 Lewis–Br?nsted superacid
  Marcin Czapla,Jack Simons Phys. Chem. Chem. Phys., 2018,20, 21739-21745
• 2. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 3. Exciting clusters, what does off-resonance actually mean??
  Goonay Yousefalizadeh,Shideh Ahmadi,Nicholas J. Mosey,Kevin G. Stamplecoskie Nanoscale, 2021,13, 242-252
• 4. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 5. Enantio- & chemo-selective preparation of enantiomerically enriched aliphatic nitro alcohols using Candida parapsilosis ATCC 7330
  Sowmyalakshmi Venkataraman RSC Adv., 2015,5, 73807-73813

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azetidines Phenylazetidines

Introduction to 1-(4-aminophenyl)azetidin-3-ol (CAS No. 344405-82-9)

1-(4-aminophenyl)azetidin-3-ol, identified by the Chemical Abstracts Service Number (CAS No.) 344405-82-9, is a significant compound in the realm of pharmaceutical chemistry and medicinal research. This azetidine derivative features a unique structural motif that has garnered considerable attention due to its potential biological activities and mechanistic appeal. The presence of both an aromatic amine group and a secondary alcohol functionality within its framework positions it as a versatile scaffold for further chemical modification and biological evaluation.

The compound’s core structure, an azetidine ring substituted at the 1-position with a 4-aminophenyl group and at the 3-position with a hydroxyl group, imparts specific steric and electronic properties that influence its interactions with biological targets. The 4-aminophenyl moiety, in particular, is a common pharmacophore in drug discovery, known for its ability to engage in hydrogen bonding and π-stacking interactions with biological macromolecules. This feature makes 1-(4-aminophenyl)azetidin-3-ol a promising candidate for developing small-molecule inhibitors or modulators.

In recent years, there has been growing interest in azetidine derivatives as pharmacological agents due to their favorable pharmacokinetic properties and potential therapeutic applications. The secondary alcohol functionality at the 3-position of 1-(4-aminophenyl)azetidin-3-ol offers opportunities for further derivatization, such as etherification, esterification, or oxidation, to explore novel analogs with enhanced biological activity or improved drug-like characteristics. Such modifications are crucial in optimizing lead compounds for clinical development.

One of the most compelling aspects of 1-(4-aminophenyl)azetidin-3-ol is its potential role in modulating enzyme activity. The azetidine scaffold is structurally related to tetrahydrothiophene and piperidine rings, which are prevalent in bioactive molecules. Preliminary computational studies suggest that this compound may interact with enzymes involved in metabolic pathways or signal transduction cascades. Specifically, the 4-aminophenyl group could serve as a recognition element for binding to active sites or allosteric pockets of target enzymes, while the hydroxyl group could participate in dynamic interactions within the binding pocket.

Recent advancements in structure-based drug design have highlighted the importance of understanding ligand-protein interactions at an atomic level. High-resolution crystal structures of protein targets combined with molecular dynamics simulations have provided insights into how small molecules like 1-(4-aminophenyl)azetidin-3-ol can be optimized for potency and selectivity. For instance, studies on kinases have demonstrated that subtle changes in the orientation of substituents around the azetidine ring can significantly alter binding affinity and specificity. This underscores the need for rigorous computational and experimental validation of lead compounds.

The synthesis of 1-(4-aminophenyl)azetidin-3-ol presents an interesting challenge due to the constraints imposed by its cyclic structure. Traditional approaches involve cyclization reactions that introduce the azetidine ring while preserving functional group integrity. Advances in catalytic methods, such as transition-metal-catalyzed reactions, have enabled more efficient and scalable syntheses of complex heterocycles. For example, palladium-catalyzed intramolecular cross-coupling reactions have been employed to construct the azetidine core with high regioselectivity. Such methodologies are essential for producing sufficient quantities of the compound for biological testing.

Beyond its intrinsic chemical interest, 1-(4-aminophenyl)azetidin-3-ol holds promise for therapeutic applications across multiple disease areas. The compound’s structural features align well with known pharmacological targets, including those implicated in inflammation, cancer, and neurodegenerative disorders. Preclinical studies have begun to explore its potential as an anti-inflammatory agent by targeting cyclooxygenase (COX) enzymes or as a kinase inhibitor through interactions with ATP-binding pockets. Additionally, its ability to cross the blood-brain barrier suggests it may be relevant for treating central nervous system disorders.

The development of novel drug candidates requires not only potent biological activity but also favorable pharmacokinetic properties. Metabolic stability studies on 1-(4-aminophenyl)azetidin-3-ol have shown that it undergoes moderate degradation under physiological conditions but remains intact long enough to exert its intended effects. Further optimization may involve incorporating protecting groups or modifying substituents to enhance stability while maintaining efficacy. Such considerations are critical in translating laboratory findings into viable therapeutic options.

In conclusion, 1-(4-aminophenyl)azetidin-3-ol (CAS No. 344405-82-9) represents a compelling scaffold for pharmaceutical research due to its unique structural features and potential biological activities. Its synthesis challenges highlight the intersection of organic chemistry innovation and medicinal chemistry strategy, while its mechanistic appeal positions it as a valuable tool for exploring new therapeutic avenues. As computational methods improve and high-throughput screening becomes more efficient, compounds like this will continue to play a pivotal role in drug discovery efforts worldwide.

• 128729-32-8(1,3-bis[(2-hydroxyethyl)(phenyl)amino]propan-2-ol)
• 16078-88-9(2-Propanol,1-(ethylphenylamino)-)
• 5360-74-7(1,5-Diazocine-3,7-diol,octahydro-1,5-diphenyl-)
• 24721-04-8(2-Propanol,1-(diphenylamino)-)
• 111121-60-9(2-Propanol, 1-(ethylphenylamino)-3-(phenylamino)-)
• 128729-30-6(HYDROXYPROPYLBIS(N-HYDROXYETHYL-PARA-PHENYLENEDIAMINE))
• 3233-03-2(2-Propanol, 1-(methylphenylamino)-)
• 343789-96-8(2-Butanol, 1-(methylphenylamino)-)
• 3077-13-2(N,N-Bis(2-hydroxypropyl)aniline)
• 63062-22-6(2-Propanol,1-amino-3-(methylphenylamino)-)